SHORT MINI-FUTURE - GENMAB | Delayed Deutsche Boerse AG 19:03:26 19/06/2024 BST | ||
| 35.18 EUR | +0.80% |
|
| Current month | +6.05% | ||
| 1 month | +10.97% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
| Date | Price | Change |
|---|---|---|
| 19/06/24 | 35.18 | +0.80% |
| 18/06/24 | 34.9 | +0.40% |
| 17/06/24 | 34.76 | +1.05% |
| 14/06/24 | 34.4 | +0.20% |
| 13/06/24 | 34.33 | +0.32% |
Delayed Quote Deutsche Boerse AG
Last update June 19, 2024 at 07:03 pm
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | GENMAB A/S |
| Issuer | 
Vontobel
|
| WKN | VU0H1X |
| ISIN | DE000VU0H1X1 |
| Date issued | 05/12/2022 |
| Strike | 4,402 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 15.89 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 35.38 € |
|---|---|
| Lowest since issue | 14.81 € |
| Spread | 0.5 € |
| Spread % | 1.40% |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
1,810
DKK
Average target price
2,464
DKK
Spread / Average Target
+36.17%
- Stock Market
- Certificates
- Certificat
